X

Drug Profile

Research programme: osteoarthritis therapy - sanofi-aventis/GPC Biotech

Latest Information Update: 24 Feb 2009

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator GPC Biotech AG; sanofi-aventis
Developer sanofi-aventis
Class
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Osteoarthritis

Most Recent Events

26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
05 May 2004 The collaboration between GPC Biotech AG and Aventis is no longer active
17 Feb 2004 A validated target has been selected for high-throughput screening

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com